8-K
filed May 15, 2026, 4:01 PM ET
ticker INDV
CIK 0001625297
leadership
confidence high
sentiment neutral
materiality 0.55
Indivior eliminates Chief Scientific Officer role; Heidbreder to depart Dec 31, 2026
Indivior Pharmaceuticals, Inc.
- CSO position eliminated effective June 1, 2026; Dr. Christian Heidbreder transitions to advisory role through year-end.
- Heidbreder's employment terminates Dec 31, 2026 as a termination without cause per existing agreement.
- At May 13 annual meeting, shareholders elected all eight director nominees with overwhelming support.
- Say-on-pay approved; frequency set to annual until 2032 unless board changes.
- Ratification of PwC as independent auditor for fiscal 2026 passed with 99.1M votes for.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Christian Heidbreder departed as Chief Scientific Officer at Indivior Pharmaceuticals, Inc..
- Action
- termination
- Role
- Chief Scientific Officer
Exact text from the filing
Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Indivior Pharmaceuticals, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-13 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
4. To ratify the appointment of PricewaterhouseCoopers LLP US (PwC) as our independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Votes Abstained Broker Non-Votes 99,146,241 1,237,984 23,497 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Indivior Pharmaceuticals, Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-05-13 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
2. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement (Say-on-Pay): Votes For Votes Against Votes Abstained Broker Non-Votes 90,364,566 1,324,996 1,248,134 7,470,026
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Indivior Pharmaceuticals, Inc. shareholders approved Election of eight director nominees each to serve for a one-year term until 2027 Annual Meeting at the 2026-05-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
1. To elect eight director nominees, each to serve for a one-year term extending until our 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified: Nominee Votes For Votes Against Votes Abstained Broker Non-Votes Dr. David Wheadon 91,378,828 1,534,064 24,804 7,470,026 Joe Ciaffoni 92,834,811 76,839 26,046 7,470,026 Dr. Keith Humphreys 92,839,955 72,084 25,657 7,470,026 Tony Kingsley 92,839,469 72,503 25,724 7,470,026 Daniel Ninivaggi 87,545,032 5,366,849 25,815 7,470,026 Barbara Ryan 91,562,195 1,302,383 73,118 7,470,026 Mark Stejbach 92,838,962 72,847 25,887 7,470,026 Juliet Thompson 92,136,342 728,040 73,314 7,470,026
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Indivior Pharmaceuticals, Inc. shareholders approved Advisory vote on preferred frequency of say-on-pay votes at the 2026-05-13 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
3. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers (Say-on-Frequency): Votes For 1 Year Votes For 2 Years Votes For 3 Years Votes Abstained Broker Non-Votes 91,848,954 21,701 1,032,941 34,100 7,470,026
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.